Abstract：
This study aims to investigate the potential role of lncRNA NR2F2-AS1 in the development of gastric cancer by affecting the levels of miR-320b and BMI1.
Gastric cancer is a high-mortality malignancy, and understanding the underlying molecular mechanisms is crucial. Non-coding RNAs play an important role in gene expression, and their dysregulation can lead to tumor initiation and progression.
This study aims to determine the pathological role of LncRNA NR2F2-AS1 in gastric cancer progression and its association with the clinicopathological characteristics of patients.
Bioinformatics databases were used to predict the expression levels and interactions between the studied factors to achieve this objective. The expression pattern of NR2F2-AS1/miR- 320b/BMI1 in 40 pairs of tumor and adjacent normal tissues was examined using RT-PCR, IHC, and western blot. The correlation, ROC curve, and survival analyses were also conducted for the aforementioned factors.
The results showed an increase of more than 2-fold for BMI-1 and lncRNA NR2F2-AS1 in lower stages, and the elevation continued with the increasing stage of the disease. This correlated with significant downregulation of miR-320b and PTEN, indicating their association with gastric cancer progression and decreased patient survival. LncRNA NR2F2-AS1 acts as an oncogene by influencing the level of miR-320b, altering the amount of BMI1. A reduction in the amount of miR-320b against lncRNA NR2F2-AS1 and BMI1 directly correlates with a reduced overall survival rate of patients, especially if this disproportion is more than 3.0. ROC curve analysis indicated that alteration in the lncRNA NR2F2-AS1 level showed more than 98.0% sensitivity and specificity to differentiate the lower from higher stages of GC and predict the early onset of metastasis.
In conclusion, these results suggest that NR2F2-AS1/miR-320b/BMI1 has the potential to be a prognostic as well as diagnostic biomarker for gastric cancer.
Gastric cancer is a high-mortality malignancy, and understanding the underlying molecular mechanisms is crucial. Non-coding RNAs play an important role in gene expression, and their dysregulation can lead to tumor initiation and progression.
This study aims to determine the pathological role of LncRNA NR2F2-AS1 in gastric cancer progression and its association with the clinicopathological characteristics of patients.
Bioinformatics databases were used to predict the expression levels and interactions between the studied factors to achieve this objective. The expression pattern of NR2F2-AS1/miR- 320b/BMI1 in 40 pairs of tumor and adjacent normal tissues was examined using RT-PCR, IHC, and western blot. The correlation, ROC curve, and survival analyses were also conducted for the aforementioned factors.
The results showed an increase of more than 2-fold for BMI-1 and lncRNA NR2F2-AS1 in lower stages, and the elevation continued with the increasing stage of the disease. This correlated with significant downregulation of miR-320b and PTEN, indicating their association with gastric cancer progression and decreased patient survival. LncRNA NR2F2-AS1 acts as an oncogene by influencing the level of miR-320b, altering the amount of BMI1. A reduction in the amount of miR-320b against lncRNA NR2F2-AS1 and BMI1 directly correlates with a reduced overall survival rate of patients, especially if this disproportion is more than 3.0. ROC curve analysis indicated that alteration in the lncRNA NR2F2-AS1 level showed more than 98.0% sensitivity and specificity to differentiate the lower from higher stages of GC and predict the early onset of metastasis.
In conclusion, these results suggest that NR2F2-AS1/miR-320b/BMI1 has the potential to be a prognostic as well as diagnostic biomarker for gastric cancer.
摘要：
目的：本研究旨在通过影响miR-320b和BMI1的水平，探讨lncRNANR2F2-AS1在胃癌发生发展中的潜在作用。
背景：胃癌是一种高死亡率的恶性肿瘤，了解潜在的分子机制至关重要。非编码RNA在基因表达中起着重要作用,它们的失调会导致肿瘤的发生和进展。
目的：本研究旨在确定LncRNANR2F2-AS1在胃癌进展中的病理作用及其与患者临床病理特征的关系。
方法：使用生物信息学数据库来预测表达水平和所研究因素之间的相互作用，以实现这一目标。用RT-PCR检测NR2F2-AS1/miR-320b/BMI1在40对肿瘤及癌旁正常组织中的表达模式,IHC,和westernblot.相关性，ROC曲线,并对上述因素进行了生存分析.
结果：结果显示BMI-1和lncRNANR2F2-AS1在较低阶段增加2倍以上，随着疾病阶段的增加，升高持续。这与miR-320b和PTEN的显著下调相关，表明它们与胃癌进展和降低患者生存率有关。LncRNANR2F2-AS1作为癌基因通过影响miR-320b的水平，改变BMI1的量。miR-320b对lncRNANR2F2-AS1和BMI1的减少与患者总体生存率的降低直接相关。特别是如果这个比例超过3.0。ROC曲线分析表明，lncRNANR2F2-AS1水平的改变显示出超过98.0％的敏感性和特异性，以区分GC的较低阶段和较高阶段并预测转移的早期发作。
结论：结论：这些结果表明NR2F2-AS1/miR-320b/BMI1有可能成为胃癌的预后和诊断生物标志物.
背景：胃癌是一种高死亡率的恶性肿瘤，了解潜在的分子机制至关重要。非编码RNA在基因表达中起着重要作用,它们的失调会导致肿瘤的发生和进展。
目的：本研究旨在确定LncRNANR2F2-AS1在胃癌进展中的病理作用及其与患者临床病理特征的关系。
方法：使用生物信息学数据库来预测表达水平和所研究因素之间的相互作用，以实现这一目标。用RT-PCR检测NR2F2-AS1/miR-320b/BMI1在40对肿瘤及癌旁正常组织中的表达模式,IHC,和westernblot.相关性，ROC曲线,并对上述因素进行了生存分析.
结果：结果显示BMI-1和lncRNANR2F2-AS1在较低阶段增加2倍以上，随着疾病阶段的增加，升高持续。这与miR-320b和PTEN的显著下调相关，表明它们与胃癌进展和降低患者生存率有关。LncRNANR2F2-AS1作为癌基因通过影响miR-320b的水平，改变BMI1的量。miR-320b对lncRNANR2F2-AS1和BMI1的减少与患者总体生存率的降低直接相关。特别是如果这个比例超过3.0。ROC曲线分析表明，lncRNANR2F2-AS1水平的改变显示出超过98.0％的敏感性和特异性，以区分GC的较低阶段和较高阶段并预测转移的早期发作。
结论：结论：这些结果表明NR2F2-AS1/miR-320b/BMI1有可能成为胃癌的预后和诊断生物标志物.
